Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
Header Image
Serotonin

Sitemap

Serotonin

Serotonin is an important neurotransmitter in the central nervous system (CNS). It also has peripheral significance (in the body). This illustration refers to serotonin in the brain.
Serotonin is involved in many neurophysiological mechanisms and has a broad regulatory range. Serotonin is required for the stress reactions of the HPA axis.
Tonic serotonergic activity is highest during periods of awakening arousal, while it is reduced during quiet wakefulness and slow-wave sleep and completely absent during REM sleep.1

1. Formation of serotonin

Peripherally (in the body), serotonin is primarily synthesized in the enterochromaffin cells of the intestinal mucosa.
It is transported in the blood by thrombocytes and basophilic granulocytes and can therefore exert its effect in almost every body tissue2
Serotonin is mainly produced in the cell bodies of neurons of the raphe nuclei.34

  • Dorsal raphe nucleus (DRN)
    • 50 % of DRN cells synthesize serotonin
  • Medial raphe nucleus (MRN)
    • 5 % of DRN cells synthesize serotonin

DRN and MRN project to numerous cortical and subcortical brain regions, in particular:5

  • Amygdala
  • Hypothalamus
  • Thalamus
  • Superior colliculus
  • mPFC
  • sensorimotor cortex
  • Putamen
  • Caudate nucleus
  • Septum

Tonic serotonin injection occurs in a rhythm of 1 to 5 peaks/second. The frequency of serotonin release is increased by noradrenaline at adrenoceptors and decreased by serotonin at the somatodendritic 5-HT-1A autoreceptors.6 Somatodendritic and presynaptic serotonin autoreceptors are part of a negative feedback loop that serves to limit excessive serotonin production.7 This negative feedback loop is impaired in some disorders.
Serotonin neurons also frequently express other neurotransmitters, in particular GABA, glutamate and nitric oxide.8

Serotonin production is increased by

  • Vitamin D39 D3 increases mood (especially in winter), even in healthy people1011
    In Germany, 60% of all people suffer from D3 deficiency. Especially in the months of October to April, the natural intensity of sunlight is not sufficient to produce enough D3. Find out more at Vitamin D3 In the article Vitamins and minerals for ADHD in the section Medication for ADHD - Overview of the chapter ADHD - treatment and therapy. ADHD sufferers are more likely than average to suffer from D3 deficiency.
  • Acetyl-L-carnitine (0.5 g/kg over 25 days) increased the serotonin level in the cortex and the noradrenaline level in the hippocampus of mice.12 GABA, glutamate and glutamine remained unchanged.
  • Zen meditation
    Meditation can increase the brain’s serotonin levels in the long term, not just during meditation itself.13

Serotonin production is reduced by

  • Stress14

2. Control ranges of serotonin

  • Impulse control151617
  • Situationally appropriate recall of behaviors, especially with regard to emotions18
    • Together with dopamine
  • Controlling the intensity of the stress response18
    • Together with dopamine
    • 5-HT particularly strongly innervates the stress-integrating structures of the forebrain, including19
      • Hippocampus
      • PFC
      • Amygdala
      • Hypothalamus
    • Deactivation (lesion) of the raphe nuclei (electrolytically or neurochemically by means of DHT) reduces the responses of the HPA axis to stress through20
      • Restriction of movement (serotonin reduction reduces ACTH secretion by 50 %)21
        • In contrast, no reduction in ACTH secretion by 5-HT antagonists in response to swimming stress, ether treatment or endotoxin.
      • Ether22; different 21
      • Administration of the 5-HT antagonist DHT into the PVN in relation to stress caused by ether22
      • Glutamate administration in the PVN23
        • Which suggests that serotonin acts directly on the PVN and mediates stress responses there
        • As well as noradrenaline (via α1-adrenoceptors)24
      • Stimulation of the dorsal hippocampus22
      • Stimulation of the central amygdala22
        • Whereby serotonin mediates this stress-inhibiting effect in the PVN via 5-HT-2 receptors24
    • Administration of a 5HT2 receptor antagonist into the amygdala inhibits ACTH synthesis in response to light stress25
      • This indicates that serotonin also activates the HPA axis via limbic structures20
  • Emotions/emotion control1426
    • Affect control18
      • Together with dopamine
    • Mood14
    • Aggression15161727
    • Anxiety15161719
    • Drive14
    • Mental well-being14
    • Emotional memory in the amygdala and limbic system14
  • Control of the stimulus intensity28
  • Low serotonin levels cause emotional deficits in ADHD29
  • Pain perception1526
  • Sleep-wake rhythm3026
  • Eating behavior1526
  • Sexual behavior3126
  • Antisocial personality disorder32
    Serotonin is important in prenatal brain development. In the early development of the CNS, serotonin influences 17
  • Cell proliferation
  • Cell migration
  • Cell differentiation

Serotonin increases prolactin and ACTH levels.33
Serotonin deficiency in the basolateral amygdala causes a decrease in long-term potentiation by increased glutamate and decreased GABA levels in adult female mice exposed to chronic 4-vinylcycloxene diepoxide, which triggers anxiety symptoms.34

3. Symptoms of serotonin deficiency

Serotonin deficiency in the brain:

  • Lack of drive14
  • Sadness14
  • Fears1435
  • Constraints1429
  • Depressive moods / depression1429135
  • Aggression161727135
  • Stomach/intestinal complaints14
    • As a messenger substance, serotonin also regulates the nervous system of the digestive tract14
    • Eating disorders / satiety35
  • Emotional deficits29
  • Inadequate executive functions29
  • Learning difficulties29
    • Memory impairment35
  • Impulse inhibition problems (if dopamine is also involved)13
  • Sleep disorders35
    Peripheral (somatic) symptoms of serotonin deficiency:35
  • Vasoconstriction (coronary spasms)
  • Irritable colon (irritable bowel syndrome)
  • Fibromyalgia (sensitivity to pain)
  • Scoliosis
  • Tendency to thrombosis (platelet aggregation)
  • Inflammation (immune dysfunction)
  • Melatonin deficiency

Serotonin deficiency in the brain and body:35

  • Headache
  • Migraine

Serotonin is also involved in schizophrenia.1
It is striking that serotonin deficiency is associated with internalizing disorders (depression, anxiety) on the one hand and externalizing disorders (aggression, impulse control, antisocial personality disorder) on the other.

4. Serotonin neurons, receptors, transporters

4.1. Serotonin receptors

The following description of the serotonin receptors is based on Jørgensen.36
To date, 7 main groups of serotonin receptors are known, 5-HT-1 to 5-HT-7, which in turn are subdivided into subgroups, e.g. 5-HT2a, 5-HT-2b, 5-TH-2c.

4.1.1. 5-HT1A

  • In the dorsal raphe nuclei and in the limbic system
  • Pre- and postsynaptic37
  • Inhibits adenylate cyclase (AC)
    • Inhibition of AC causes memory and learning defects.38
    • Inhibition of AC by binding to the Opiate receptor
    • Inhibition of AC contributes to the development of addiction38
    • Toxins such as cholera toxin and pertussis toxin act by permanently activating adenylate cyclase.38
  • Autoreceptor
    • Presynaptically on somatodendritic serotonin neurons in the raphe nuclei39
    • Inhibits serotonin production in the raphe nuclei4039
  • Regulated
    • Mood
      • Depression
      • Suicide
    • Fear
    • Temperature
    • Feeding
    • Movement
    • Aggression (5-HT1A receptor reduced)41
    • Anorexia (5-HT1A receptor elevated)42
  • High densities of postsynaptic 5-HT1A receptors in:41
    • Hippocampus
    • Septum
    • Amygdala
    • Entorhinal cortex
    • Frontal cortex
  • Predominantly inhibiting40
  • Agonists:
    • 5-CT
    • 8-OH-DPAT
    • RU 24969
  • Antagonists:
    • WAY-100635
    • Cyanopindolol
    • Metysergide
  • Stress
    • Acute stress decreased the gene expression of the 5-HT1A receptor43 while the gene expression of the 5-HT7 receptor in the CA1 region of the hippocampus increased44
    • Corticosterone dose-dependently influences 5-HT1A receptor-mediated responses in the rat hippocampus in vitro and in vivo: activation of only the high-affinity mineralocorticoid receptor suppresses 5-HT1A receptor-mediated responses, while additional activation of lower-affinity glucocorticoid receptors enhances the effect of 5-HT.45
    • Glucocorticoid-mediated chronic stress downregulated 5-HT1A receptors in the hippocampus in animals.45
  • Functional variations in the 5-HT1A gene (HTR1A) appear to be associated with46
    • Personality traits of negative emotionality
    • The development of anxiety disorders
  • 5-HT1A activation decreases NMDA receptor-mediated currents in pyramidal neurons of the PFC.46

4.1.2. 5-HT1B

  • In substantia nigra, basal ganglia, frontal cortex
  • Regulated
    • Neurotransmitter release
      • Activation of 5-HT1B inhibits transmitter release.
        This significantly reduces excitatory transmission in the thalamocortical regions of the visual and somatosensory systems.
        5-HT1B receptors thus appear to regulate the development of the thalamic cortex by inhibiting glutamate release.46
      • 5-HT filters glutamatergic input from the cortex and thalamus into the basolateral amygdala by activating presynaptic 5-HT1B receptors, not 5-HT1A receptors.47
    • Vascular functions
  • Predominantly inhibiting48
  • Agonists:
    • 5-CT
    • RU 24969
  • Antagonists:
    • Cyanopindolol

4.1.3. 5-HT2A

  • In the cortex, hippocampus, caudate nucleus
  • Stimulates phospholipase
  • Regulated
    • Sleep
    • Motor functions
    • Behavior
  • Facilitating mainly other modes of action48
  • Agonists:
    • DOI
    • MCPP
    • S-α-methyl-serotonin / Sα-methyl-5-HT
  • Antagonists:
    • Metergoline
    • Metysergide
    • Flourobenzoyl
    • Ketanserin
      • Administration of the 5HT2 receptor antagonist ketanserin into the amygdala inhibits ACTH synthesis in response to light stress25
        • This indicates that serotonin also activates the HPA axis via limbic structures20
    • LY 53857
    • Quetiapine, Seroquel (antipsychotic)
  • Serotonin acts on 5-HT2A to inhibit the release of dopamine. 5-HT2A antagonists prevent this.
  • Serotonin supports the exitatory effects of glutamate in the nucleus motorius nervi facialis, which controls motor processes and facial expressions. This support is prevented by 5-HT2 antagonists.49
  • 5-HT2A and 5-HT2C receptors appear to be easily downregulated during chronic activation, but are not subject to upregulation during chronic underactivation. In addition, chronic treatment with serotonin antagonists leads to a paradoxical downregulation of 5-HT2A and 5-HT2C receptors.40
  • 5-HT2A activation increases NMDA receptor-mediated currents in pyramidal neurons of the PFC((Lesch, Waider (2012): Serotonin in the Modulation of Neural Plasticity and Networks: Implications for Neurodevelopmental Disorders. Neuron VOLUME 76, ISSUE 1, P175-191, OCTOBER 04, 2012 DOI:https://doi.org/10.1016/j.neuron.2012.09.013
  • 5-HT1A and 5-HT2A receptors appear to work together in the brain50
    • 5-HT2A and 5-HT1A receptors are highly colocalized in the frontal cortex of rodents
    • Balance between postsynaptic 5-HT1A and 5-HT2A receptor activity on neurons can modulate descending excitatory input to limbic and motor structures
    • 5-HT1A and 5-HT2A receptors appear to fine-tune cortical systems that modulate behavioral inhibition and self-control.
    • A relative increase in 5-HT1A receptor activity compared to 5-HT2A receptor binding could potentially contribute to the behavioral inhibition and overcontrol commonly seen in eating disorders
    • An imbalance between the mesial-temporal (amygdala) and cingulate 5HT1A/2A receptors may be a feature of anorexia subgroups and may be related to behavioral inhibition, anticipatory anxiety, or the integration of cognition and mood
    • Together they regulate the inhibition of exploration of new environments

4.1.4. 5-HT2B

  • Facilitating predominantly other modes of action48
  • Agonists:
    • S-α-methyl-serotonin / Sα-methyl-5-HT

4.1.5. 5-HT2C

  • In Hypothalamus, Limbic system, Basal ganglia
  • Regulated
    • Synaptic plasticity (decisive)46
    • Erection of the penis
  • Facilitating predominantly other modes of action48
  • Agonists:
    • DOI
    • MCPP
    • MK 21
    • S-α-methyl-serotonin / Sα-methyl-5-HT
  • Antagonists:
    • Metergoline
    • Metysergide
    • Ketanserin
      • Administration of the 5HT2 receptor antagonist ketanserin into the amygdala inhibits ACTH synthesis in response to light stress25
        • This indicates that serotonin also activates the HPA axis via limbic structures20
    • LY 53857
    • SB 242084
    • Quetiapine / Seroquel (antipsychotic)
  • 5-HT2A and 5-HT2C receptors appear to be easily downregulated during chronic activation, but are not subject to upregulation during chronic underactivation. In addition, chronic treatment with serotonin antagonists leads to a paradoxical downregulation of 5-HT2A and 5-HT2C receptors.40
  • 5-HT2C activation increases NMDA receptor-mediated currents in pyramidal neurons of the PFC.46

4.1.6. 5-HT3

  • In pons, brain stem,36 entorhinal cortex, area postrema40
  • Regulated
    • Vomiting reflex
    • Gastrointestinal movements (e.g. bowel movements)
    • Cardiovascular system
    • Pain perception51
    • Reward system51
    • Cognition51
    • Depression51
    • Anxiety control51
  • Fast excitatory effect48
  • Agonists:
    • SR 57227
    • M-CPBG
    • Y-25130
    • Ondansetrone
    • ICS 205-930
  • Stimulation of 5-HT3 receptors in the striatum increases endogenous dopamine release.6
  • 5-HT3R antagonists51
    • Inhibit the binding of serotonin to postsynaptic 5-HT3 receptors
    • Increase the availability of serotonin for other receptors such as 5-HT1A, 1B and 1D as well as 5-HT2
    • Have an antidepressant effect
    • Play an important role in mood and stress disorders

4.1.7. 5-HT4

  • In cortex, hypothalamus
  • Regulated
    • Memory
    • Neurotransmitter release
  • Facilitates other active sequences48
  • Agonist:
    • RS 67506
  • Antagonists:
    • ICS 205-930
    • RS 2359

4.1.8. 5-HT5A

  • In cortex, hippocampus, hypothalamus
  • Regulated
    • Sleep
    • Motor functions
    • Behavior
  • Agonists:
    • 5-CT

4.1.9. 5-HT5B

  • In the dorsal raphe nuclei, in the CA 1 region of the hippocampus, olfactory bulb
  • Regulated
    • Unknown

4.1.10. 5-HT6

  • In striatum, hippocampus, cortex
  • Regulated
    • Cholinergic system
    • Feeding
  • Antagonists:
    • Metergoline

4.1.11. 5-HT7

  • In Limbic system, suprachiasmatic nucleus, dorsal raphe nuclei
  • Regulated
    • Mood
    • Fear
    • Temperature
    • Sleep cycles
  • Facilitates other active sequences48
  • Agonists:
    • 5-CT
    • 8-OH-DPAT
  • Antagonists:
    • Metergoline
    • Metysergide
  • Stress
    • Acute stress increased the gene expression of the 5-HT7 receptor in the CA1 region of the hippocampus,44 while the gene expression of the 5-HT1A receptor decreased43

4.2. Effect of antidepressant medication and treatment on receptors

The following presentation is based on Cooper et al.52

4.2.1. Somatodendritic 5-HT-1A autoreceptor

  • SSRI: long-term use reduces receptor sensitivity
  • MAO-A reuptake inhibitors: long-term use reduces receptor sensitivity
  • 5-HT-1A agonists: long-term use reduces receptor sensitivity
  • Tricyclic antidepressants: no effect
  • Electroconvulsive therapy: no effect
    The effects of SSRIs, MAO-A reuptake inhibitors and 5-HT-1A agonists could be understood as a reduction in upregulation of the receptor to serotonin deficiency.

4.2.2. Presynaptic 5-HT autoreceptors

  • SSRI: long-term use reduces receptor sensitivity
  • MAO-A reuptake inhibitors: no effect
  • 5-HT-1A agonists: no effect
  • Tricyclic antidepressants: no effect
  • Electroconvulsive therapy: no effect

4.2.3. Preynaptic alpha-2 adrenoceptors

  • SSRI: no effect
  • MAO-A reuptake inhibitors: long-term use reduces receptor sensitivity
  • Electroconvulsive therapy: no effect

4.2.4. Postsynaptic 5-HT receptors

  • SSRI: no effect
  • MAO-A reuptake inhibitors: no effect or reduced receptor sensitivity due to long-term use
  • 5-HT-1A agonists: no effect
  • Tricyclic antidepressants: long-term use increases receptor sensitivity
  • Electroconvulsive therapy: long-term treatment increases receptor sensitivity

4.2.5. Change in serotonin levels

  • SSRI: increase
  • MAO-A reuptake inhibitors: increase
  • 5-HT-1A agonists: increase
  • Tricyclic antidepressants: increase
  • Electroconvulsive therapy: increase

5. Reuptake and breakdown of serotonin

5.1. Serotonin transporter

Psychosocial stress led to significantly lower gray matter volume in the precentral gyrus, middle and superior frontal gyri, frontal pole and cingulate gyrus in carriers of the S allele of the serotonin transporter than in carriers of the L allele. The volume of gray matter in the frontal pole and anterior cingulate gyrus mediated the association of this gene-environment interaction with the number of ADHD symptoms.53

The GR-9β haplotype of the glucocorticoid receptor gene NR3C1 is associated with an increased risk of ADHD. In carriers of this haplotype, stress exposure and ADHD severity correlate more strongly than in non-carriers. This gene-environment interaction is even stronger if they were also carriers of the homozygous 5-HTTLPR L allele instead of the S allele. These two- and three-way interactions were reflected in the gray matter volume of the cerebellum, the parahippocampal gyrus, the intracalcarine cortex and the angular gyrus. This proves that gene variants in the stress response pathway of the HPA axis influence how stress exposure affects the severity of ADHD and brain structure.54

5.2. Serotonin degradation

Serotonin is broken down by

  • MAO-A (main degradation pathway)
  • MAO-B
  • Aldehyde dehydrogenases
  • Acetylation
    • subsequent methylation to melatonin by serotonin-N-acetyltransferase (AANAT) and acetylserotonin-O-methyltransferase (ASMT) with consumption of the methyl group donor S-adenosylmethionine (SAM)

Serotonin is broken down to 5-HIAA (5-hydroxyindolylacetic acid).

6. Serotonin and ADHD

ADHD is primarily dopaminergic and secondarily noradrenergic. There is a further, albeit smaller, connection to the serotonergic system.
Serotonin is therefore involved to a lesser extent in ADHD and is said to be more relevant in ADHD-I (without hyperactivity).55

However, we wonder whether serotonin deficiency could contribute to the frequently flattened HPA responses seen in ADHD-HI. It remains to be seen how this can be reconciled with the frequently exaggerated HPA axis responses in ADHD-I.

One study of children with ADHD found that increased methylation of the promoter of the serotonin transporter gene correlated with increased hyperactivity and impulsivity and increased impulsive errors in a sustained attention task.56 In contrast, another study found that lower methylation of the serotonin transporter gene (and the DRD4 gene) in newborns correlated with increased ADHD symptoms at 6 years of age57
Empirically, an effect of serotonergic medication on impulsivity is known.

The dopamine transporters (DAT), which are primarily located in the striatum and are overactivated in ADHD, also have a serotonergic affinity in the striatum and therefore also take up serotonin again,58 at least when serotonin transporter activity is restricted.59
An increase in serotonin caused directly in the striatum also increased the concentration of dopamine in the striatum.60

Taking methylphenidate is said to have an effect on serotonin levels.29

7. Other mental disorders due to malfunctions of the serotonergic system

  • Depression6162
  • Anxiety disorders462
  • Schizophrenia462
  • Addictive disorders462
  • Childhood autism63641765
  • Eating disorders62
  • Vomiting62
  • Obsessive-compulsive disorders6762
  • Cancer62
  • Circadian rhythm disturbances62
  • Developmental disorders62
  • Migraine62
  • Neurodegenerative disorders62
  • Muscle twitching (myoclonus)62
  • Sensitivity to pain62
  • Premenstrual syndrome62
  • Post-traumatic stress disorder62
  • Sexual disorders62
  • Sleep disorders62
  • Stress disorders62
    • Activation of serotonin 5-HT-1A receptors in the dorsomedial hypothalamus inhibits stress-induced activation of the HPA axis in rats.68

8. Treatment with serotonergic medication (disorders)

  • Depression67
  • Obsessive-compulsive disorders67
  • Anxiety and panic disorders67

  1. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 291

  2. DocCheck Flexikon: Serotonin. Deutsch

  3. De Deurwaerdère P, Di Giovanni G (2017): Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Prog Neurobiol. 2017 Apr;151:175-236. doi: 10.1016/j.pneurobio.2016.03.004. PMID: 27013075. REVIEW

  4. Lesch (2001): Serotonergic gene expression and depression: implications for developing novel antidepressants. Journal of Affective Disorders 2001;62:57-76

  5. Hale MW, Lowry CA (2011): Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology (Berl). 2011 Feb;213(2-3):243-64. doi: 10.1007/s00213-010-2089-z. Epub 2010 Nov 19. PMID: 21088958. REVIEW

  6. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 290, 295

  7. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 290

  8. Aquili L (2020): The Role of Tryptophan and Tyrosine in Executive Function and Reward Processing. Int J Tryptophan Res. 2020 Oct 22;13:1178646920964825. doi: 10.1177/1178646920964825. PMID: 33149600; PMCID: PMC7586026. REVIEW

  9. Patrick, Ames (2014): Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. The FASEB Journal 2014 28:6, 2398-2413

  10. Lansdowne, Provost (1998): Vitamin D3 enhances mood in healthy subjects during winter Psychopharmacology (1998) 135: 319. https://doi.org/10.1007/s002130050517

  11. Partonen (1998): Vitamin D and serotonin in winter, Medical Hypotheses, Volume 51, Issue 3, 1998, Pages 267-268, ISSN 0306-9877, https://doi.org/10.1016/S0306-9877(98)90085-8.

  12. Smeland, Meisingset, Borges, Sonnewald (2012): Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem Int. 2012 Jul;61(1):100-7. doi: 10.1016/j.neuint.2012.04.008.

  13. Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, Springer, Seite 86, mit weiteren Nachweisen

  14. Simchen, Helga: http://helga-simchen.info/Thesen-zu-ADS; dort: was bewirken die Botenstoffe?

  15. Lucki (1998): The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151-162.

  16. Ewald, Flint, Degn, Mors, Kruse (1997):. A functional variant of the serotonin transporter gene in families with bipolar affective disorder. J Affect Disord 1997;48:135-144.

  17. Lesch, Mössner (1998): Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998;44:179-192

  18. Rensing, Koch, Rippe, Rippe (2006): Der Mensch im Stress; Psyche, Körper, Moleküle; Elsevier Spektrum (heute: Springer), Kapitel 4: neurobiologische Grundlagen von Stressreaktionen, Seite 82

  19. Lowry (2002): Functional Subsets of Serotonergic Neurones: Implications for Control of the Hypothalamic‐Pituitary‐Adrenal Axis. Journal of Neuroendocrinology, 14: 911-923. doi:10.1046/j.1365-2826.2002.00861.x

  20. Herman, Figueiredo, Mueller, Ulrich-Lai, Ostrander, Choi, Cullinan (2003): Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol. 2003 Jul;24(3):151-80.

  21. Jørgensen, Knigge, Kjær, Vadsholt, Warberg (1998): Serotonergic involvement in stress-induced ACTH release, Brain Research, Volume 811, Issues 1–2, 1998, Pages 10-20, ISSN 0006-8993

  22. Feldman, Conforti, Melamed (1987): Paraventricular nucleus serotonin mediates neurally stimulated adrenocortical secretion, Brain Research Bulletin, Volume 18, Issue 2, 1987, Pages 165-168, ISSN 0361-9230, https://doi.org/10.1016/0361-9230(87)90186-9

  23. Feldman, Weidenfeld (1997): Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary-adrenocortical axis, Journal of Neural Transmission (1997) 104: 633. https://doi.org/10.1007/BF01291881

  24. Feldman, Weidenfeld (1998): The Excitatory Effects of the Amygdala on Hypothalamo-Pituitary-Adrenocortical Responses Are Mediated by Hypothalamic Norepinephrine, Serotonin, and CRF-41, Brain Research Bulletin, Volume 45, Issue 4, 1998, Pages 389-393, ISSN 0361-9230, https://doi.org/10.1016/S0361-9230(97)00384-5.

  25. Feldman, Newman, Gur, Weidenfeld (1998): Role of serotonin in the amygdala in hypothalamo-pituitaryadrenocortical responses. NeuroReport: June 22nd, 1998 – Volume 9 – Issue 9 – p 2007–2009

  26. Schloss, Williams (1998): The serotonin transporter: a primary target for antidepressant drugs. Psychopharmacology 1998;12:115-121

  27. Hinghofer-Szalkay: Humoral-neuronale Steuerung und Kontrolle von Organsystemen: Azetylcholin, Amine, Purine, Peptide, lokale Mediatoren

  28. Oades, Röpcke (2000).: Neurobiologische Grundlagen der Aufmerksamkeit: „Über die Freiheit der Wahl“. Sprache – Stimme – Gehör 24 (2000) 49 – 56

  29. Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, Springer, Seite 86

  30. Becker (2007): Zusammenhang zwischen der Lautstärkeabhängigkeit akustisch evozierter Potentiale und dem 5-HTTLPR, Dissertation, Seite 6, mit Verweis auf Lucki (1998): The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151-162.

  31. Becker (2007): Zusammenhang zwischen der Lautstärkeabhängigkeit akustisch evozierter Potentiale und dem 5-HTTLPR, Dissertation, Seite 6, mit Verweis auf Lucki (1998): The spectrum of behaviors influenced by serotonin. Biol Psychiatry1998;44:151-162.

  32. Ivanov, Flory, Newcorn, Halperin (2018): Childhood serotonergic function and early adult outcomes in youth with ADHD: A 15-year follow-up study. Eur Neuropsychopharmacol. 2018 Nov 16. pii: S0924-977X(18)30813-7. doi: 10.1016/j.euroneuro.2018.09.001.

  33. Jørgensen (2007): Studies on the neuroendocrine role of serotonin. Dan Med Bull. 2007 Nov;54(4):266-88.

  34. Wang, Liu, Xiong, Di, Yuan, Wu, Chen (2019): Reduced serotonin impairs long-term depression* (*gemeint ist wohl: potentation) in basolateral amygdala complex and causes anxiety-like behaviors in a mouse model of perimenopause. Exp Neurol. 2019 Aug 1;321:113030. doi: 10.1016/j.expneurol.2019.113030.

  35. Römmler (2005): Das Serotonin-Defizit-Syndrom

  36. Jørgensen (2007): Studies on the neuroendocrine role of serotonin; Dan Med Bull 2007;54:266-88

  37. Lesch, Waider (2012): Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron. 2012 Oct 4;76(1):175-91. doi: 10.1016/j.neuron.2012.09.013

  38. Spektrum.de: Adenylatcyclase

  39. Staley JK, Malison RT, Innis RB (1998): Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry. 1998 Oct 1;44(7):534-49. doi: 10.1016/s0006-3223(98)00185-1. PMID: 9787877.

  40. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 295

  41. Lanfumey L, Hamon M (2000): Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl Med Biol. 2000 Jul;27(5):429-35. doi: 10.1016/s0969-8051(00)00107-4. PMID: 10962246. REVIEW

  42. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, Wagner A, Thornton L, Hoge J, Ziolko SK (2007): Becker CR, McConaha CW, Kaye WH. Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry. 2007 May 1;61(9):1090-9. doi: 10.1016/j.biopsych.2006.07.018. PMID: 17241616.

  43. Lopez et al. 1999 nach Jørgensen (2007): Studies on the neuroendocrine role of serotonin. Dan Med Bull. 2007 Nov;54(4):266-88.

  44. Yau et al. 2001 nach Jørgensen (2007): Studies on the neuroendocrine role of serotonin. Dan Med Bull. 2007 Nov;54(4):266-88.

  45. Meijer, Kortekaas, Oitzl, de Kloet (1998): Acute rise in corticosterone facilitates 5-HT1A receptor-mediated behavioural responses. European Journal of Pharmacology, Volume 351, Issue 1, 1998, Pages 7-14, ISSN 0014-2999, https://doi.org/10.1016/S0014-2999(98)00289-1.

  46. Lesch, Waider (2012): Serotonin in the Modulation of Neural Plasticity and Networks: Implications for Neurodevelopmental Disorders. Neuron VOLUME 76, ISSUE 1, P175-191, OCTOBER 04, 2012 DOI:https://doi.org/10.1016/j.neuron.2012.09.013

  47. Guo, O’Flaherty, Rainnie (2017): Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology. 2017 Nov;126:224-232. doi: 10.1016/j.neuropharm.2017.09.013.

  48. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 297

  49. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 296

  50. Kaye W (2008): Neurobiology of anorexia and bulimia nervosa. Physiol Behav. 2008 Apr 22;94(1):121-35. doi: 10.1016/j.physbeh.2007.11.037. Epub 2007 Nov 29. PMID: 18164737; PMCID: PMC2601682. REVIEW

  51. Bhatt, Devadoss, Manjula, Rajangam (2021): 5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders. Curr Neuropharmacol. 2021;19(9):1545-1559. doi: 10.2174/1570159X18666201015155816. PMID: 33059577.

  52. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 292

  53. van der Meer, Hoekstra, Zwiers, Mennes, Schweren, Franke, Heslenfeld, Oosterlaan, Faraone, Buitelaar, Hartman (2015): Brain Correlates of the Interaction Between 5-HTTLPR and Psychosocial Stress Mediating Attention Deficit Hyperactivity Disorder Severity. Am J Psychiatry. 2015 Aug 1;172(8):768-75. doi: 10.1176/appi.ajp.2015.14081035. PMID: 25998280. n = 701

  54. van der Meer, Hoekstra, Bralten, van Donkelaar, Heslenfeld, Oosterlaan, Faraone, Franke, Buitelaar, Hartman (2016): Interplay between stress response genes associated with attention-deficit hyperactivity disorder and brain volume. Genes Brain Behav. 2016 Sep;15(7):627-36. doi: 10.1111/gbb.12307. PMID: 27391809.

  55. Simchen, Helga: http://helga-simchen.info/Thesen-zu-ADS; dort: was bewirken die Botenstoffe?; Abschnitt 8

  56. Park, Lee, Kim, Cho, Yun, Han, Cheong, Kim (2015): Associations between serotonin transporter gene (SLC6A4) methylation and clinical characteristics and cortical thickness in children with ADHD. Psychol Med. 2015 Oct;45(14):3009-17. doi: 10.1017/S003329171500094X. PMID: 26017091.

  57. van Mil, Steegers-Theunissen, Bouwland-Both, Verbiest, Rijlaarsdam, Hofman, Steegers, Heijmans, Jaddoe, Verhulst, Stolk, Eilers, Uitterlinden, Tiemeier (2014): DNA methylation profiles at birth and child ADHD symptoms. J Psychiatr Res. 2014 Feb;49:51-9. doi: 10.1016/j.jpsychires.2013.10.017. PMID: 24290898.

  58. Jackson, Wightman (1995): Dynamics of 5-hydroxytryptamine released from dopamine neurons in the caudate putamen of the rat. Brain Research. 1995; 674: 163-166

  59. Norrholm, Horton, Dwoskin (2007): The Promiscuity of the Dopamine Transporter: Implications for the Kinetic Analysis of [3H]Serotonin Uptake in Rat Hippocampal and Striatal Synaptosomes; Neuropharmacology. 2007 Dec; 53(8): 982–989. doi: 10.1016/j.neuropharm.2007.10.001, PMCID: PMC2245871, NIHMSID: NIHMS35794

  60. De Deurwaerdère, Bonhomme, Lucas, Le Moal, Spampinato (1996): Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. Journal of Neurochemistry. 1996; 66: 210-215

  61. Becker (2007): Zusammenhang zwischen der Lautstärkeabhängigkeit akustisch evozierter Potentiale und dem 5-HTTLPR, Dissertation, Seite 10, mit Verweis auf Owens & Nemeroff, 1994

  62. Cooper, Bloom, Roth (2003): The Biochemical Basis of Neuropharmacology, Seite 299

  63. Ewald, Flint, Degn, Mors, Kruse (1997):. A functional variant of the serotonin transporter gene in families with bipolar affective disorder. J Affect Disord 1997;48:135-144

  64. Becker (2007): Zusammenhang zwischen der Lautstärkeabhängigkeit akustisch evozierter Potentiale und dem 5-HTTLPR, Dissertation, Seite 6

  65. Heninger (1995): Indoleamines: The role of serotonin in clinical disorders. In: Psychopharmacology: the Fourth Generation of Progress. 1995; pp. 471-482.

  66. Cloninger (1987): Neurogeneric adaptive mechanisms in alcoholism. Science 1987;236:410-416

  67. Blier, de Montigny (1999): Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):91S-98S

  68. Stamper, Hassell, Kapitz, Renner, Orchinik, Lowry (2017): Activation of 5-HT1A receptors in the rat dorsomedial hypothalamus inhibits stress-induced activation of the hypothalamic-pituitary-adrenal axis. Stress. 2017 Mar;20(2):223-230. doi: 10.1080/10253890.2017.1301426. PMID: 28345385.